Post-approval studies (Phase 4)Study completedNCT00654875
What this trial is testing
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
Who this might be right for
Essential Hypertension
Novartis 328